No Data
No Data
MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory
MindBio Is Exploring Dual Listing on A Senior Exchange With Multiple Phase 2B Clinical Trials Underway Supported by Positive Trial Data and Planning for Phase 3
Lender Requests to Convert Loan to MindBio Shares
MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients With Major Depressive Disorder
MindBio Therapeutics Team Members Honoured With Industry Leading Awards
MindBio Therapeutics Corp: INTERIM MDA EN